China Resources Shuanghe Pharmaceutical Co., Ltd., founded in 1939 as a famous trademark in Beijing, became a pillar enterprise of the chemical drug platform in the pharmaceutical sector of China Resources Group in 2010, mainly engaged in infusion/cardiovascular and cerebrovascular/endocrine/pediatric and other fields of large-scale modern pharmaceutical listed companies
China Resources Shuanghe Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Shuanghe") is a pharmaceutical company with a glorious history of 75 years, formerly known as Beijing Pharmaceutical Factory, which was listed on the Shanghai Stock Exchange in 1997 with the stock code 600062. In 2010, CR Shuanghe entered China Resources (Holdings) Co., Ltd., one of the world's top 500 enterprises, and became a pillar enterprise of the chemical drug platform in the pharmaceutical sector of China Resources Group. In 2012, the company officially changed its name from "Beijing Shuanghe Pharmaceutical Co., Ltd." to "China Resources Shuanghe Pharmaceutical Co., Ltd."
The company has always adhered to the corporate tenet of "caring for the public, health and people's livelihood", making great efforts to govern and sticking to the faith. Today, CR Shuanghe has developed into a large-scale modern group-type pharmaceutical listed company with more than 10 subsidiaries and more than 12,000 employees, and its main products focus on infusion, cardiovascular and cerebrovascular, endocrine and pediatric fields, including compound reserpine triamterene tablets (No. 0), gliquinone tablets (sugar sippine), hydroxyethyl starch (200/0.5) sodium chloride injection (Yingyuan), levofloxacin mesylate (Lifosun), piperacillin sodium for injection, sulbactam sodium (4:1) (Yijun), Pitavastatin calcium tablets (Guanshuang), bovine lung surfactant for injection (Kelisu), pediatric compound amino acid injection and other well-known products.
As one of the first batch of state-owned enterprises in China and the first state-owned pharmaceutical company to pass GMP certification, the company has established a scientific and rigorous quality assurance system, and is committed to providing the public with drugs with definite efficacy and remarkable effects. In 2014, the company continued to improve the social responsibility management mechanism, established and improved the four-in-one social responsibility organization and management system, and was awarded the title of "Five-star Enterprise of Social Responsibility in China's Industrial Industry", and successively won the "G20 Excellent Enterprise".
In 2014, with the theme of "strategic guidance, organizational improvement, reform and development", the company comprehensively promoted the orderly development of various tasks around strategy deepening, lean management, internal and external collaboration, full performance, and team building. This year, the company achieved a main business income of 4.23 billion yuan and a net profit of 540 million yuan. In 2015, China Resources Group put forward the "5M" management requirements, and the company will develop scientifically from the perspective of "5M", continue to forge ahead, and aspire to be the leader of China's pharmaceutical industry, and make China Resources Shuanghe "solid, stronger, bigger, better and longer".
